期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; 53 (2)
Natural killer (NK) cell activation is regulated by activating and inhibitory receptors that facilitate diseased cell recognition. Among activating re......
期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; 53 (3)
T helper (Th) 9 cells, characterized by robust secretion of IL-9, have been increasingly associated with allergic diseases. However, whether and how T......
期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; ()
Foxp3(+) regulatory T (Treg) cells are indispensable for the maintenance of immunologic self-tolerance as well as for the confinement of autoimmune in......
期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; ()
Effective vaccines that function through humoral immunity seek to produce high-affinity antibodies. Our previous research identified the single-nucleo......
期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; 53 (10)
Mesenchymal stromal cells (MSCs) have long been considered a potential tool for treatment of allergic inflammatory diseases, owing to their immunomodu......
期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; ()
Signal regulatory protein alpha (SIRPa) is a crucial inhibitory regulator expressed on the surface of myeloid cells, including macrophages, dendritic ......
期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; ()
COVID-19 is a systemic inflammatory disease initiated by SARS-CoV-2 virus infection. Multiple vaccines against the Wuhan variant of SARS-CoV-2 have be......
期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; 53 (1)
The thioredoxin (TRX) system is an important contributor to cellular redox balance and regulates cell growth, apoptosis, gene expression, and antioxid......
期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; 53 (1)
Mast cells are granulated immune sentinels responsible for allergic inflammation. Allergen-induced Fc epsilon RI-signaling leads to rapid degranulatio......
期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; 53 (4)
Recurrent respiratory papillomatosis (RRP), a rare chronic disease caused primarily by human papillomavirus types 6 and 11, consists of repeated growt......
期刊： EUROPEAN JOURNAL OF IMMUNOLOGY, 2023; ()
There is no doubt that immunotherapy, particularly immune checkpoint blockade (ICB), has drastically improved treatment of metastatic cancer patients.......
